The role of acid inhibition in eradication Helicobacter pylori

Infection of the stomach by the gastric pathogen results Helicobacter pylori in chronic active gastritis and leads to the development of gastric and duodenal ulcer disease and gastric adenocarcinoma. Eradication of H. infection improves or resolves the associated pathology. Current pylori treatments of infection rely on acid suppression in combination H. pylori with at least two antibiotics. The role of acid suppression in eradication therapy has been variously attributed to antibacterial activity of proton pump inhibitors directly or through inhibition of urease activity or increased stability and activity of antibiotics. Here we discuss the effect of acid suppression on enhanced replicative capacity of to permit the H. pylori bactericidal activity of growth-dependent antibiotics. The future of eradication therapy will rely on improvement of acid inhibition along with current antibiotics or the development of novel compounds targeting the organism’s ability to survive in acid.

[1]  D. Forman,et al.  Eradication therapy for peptic ulcer disease in Helicobacter pylori-positive people. , 2016, The Cochrane database of systematic reviews.

[2]  M. Iwamuro,et al.  Letter: promising results of Helicobacter pylori eradication with vonoprazan‐based triple therapy after failure of proton pump inhibitor‐based triple therapy , 2016, Alimentary pharmacology & therapeutics.

[3]  Jason Y. Park,et al.  Review article: the global emergence of Helicobacter pylori antibiotic resistance , 2015, Alimentary pharmacology & therapeutics.

[4]  S. Y. Kim,et al.  Antibiotic treatment for Helicobacter pylori: Is the end coming? , 2015, World journal of gastrointestinal pharmacology and therapeutics.

[5]  Y. Sakurai,et al.  Acid‐inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects ‐ a randomised open‐label cross‐over study , 2015, Alimentary pharmacology & therapeutics.

[6]  Chien-Wei Lu,et al.  High-dose dual therapy is superior to standard first-line or rescue therapy for Helicobacter pylori infection. , 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[7]  Sung Woon Park,et al.  Clarithromycin-Based Standard Triple Therapy Can Still Be Effective for Helicobacter pylori Eradication in Some Parts of the Korea , 2014, Journal of Korean medical science.

[8]  K. Murakami,et al.  Tu1056 A Phase 3, Double-Blind Study of a Triple Therapy With TAK-438, Amoxicillin, and Clarithromycin As First Line Eradication of H. pylori and a Triple Therapy With TAK-438, Amoxicillin, and Metronidazole As Second Line Eradication of H. pylori , 2014 .

[9]  G. Sachs,et al.  The effects of varying acidity on Helicobacter pylori growth and the bactericidal efficacy of ampicillin , 2012, Alimentary pharmacology & therapeutics.

[10]  H. Miyajima,et al.  Rabeprazole 10 mg q.d.s. decreases 24‐h intragastric acidity significantly more than rabeprazole 20 mg b.d. or 40 mg o.m., overcoming CYP2C19 genotype , 2012, Alimentary pharmacology & therapeutics.

[11]  G. Sachs,et al.  Characterization of a Novel Potassium-Competitive Acid Blocker of the Gastric H,K-ATPase, 1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine Monofumarate (TAK-438) , 2011, Journal of Pharmacology and Experimental Therapeutics.

[12]  C. Shun,et al.  Role of Omeprazole Dosage and Cytochrome P450 2C19 Genotype in Patients Receiving Omeprazole‐Amoxicillin Dual Therapy for Helicobacter pylori Eradication , 2011, Pharmacotherapy.

[13]  F. Cavalli,et al.  Long-term outcome following Helicobacter pylori eradication in a retrospective study of 105 patients with localized gastric marginal zone B-cell lymphoma of MALT type. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  D. Graham,et al.  A Report Card to Grade Helicobacter pylori Therapy , 2007, Helicobacter.

[15]  G. Sachs,et al.  Gene expression in vivo shows that Helicobacter pylori colonizes an acidic niche on the gastric surface , 2007, Proceedings of the National Academy of Sciences.

[16]  J. J. Tai,et al.  Long-term results of anti-Helicobacter pylori therapy in early-stage gastric high-grade transformed MALT lymphoma. , 2005, Journal of the National Cancer Institute.

[17]  David R. Scott,et al.  The Periplasmic α-Carbonic Anhydrase Activity of Helicobacter pylori Is Essential for Acid Acclimation , 2005, Journal of bacteriology.

[18]  P. De Paoli,et al.  Analysis of Antimicrobial Susceptibility and Virulence Factors in Helicobacter pylori Clinical Isolates , 2004, Journal of chemotherapy.

[19]  J. Foster,et al.  GadE (YhiE) activates glutamate decarboxylase‐dependent acid resistance in Escherichia coli K‐12 , 2003, Molecular microbiology.

[20]  K. Ohashi,et al.  Therapeutic impact of CYP2C19 pharmacogenetics on proton pump inhibitor-based eradication therapy for Helicobacter pylori. , 2003, Methods and findings in experimental and clinical pharmacology.

[21]  P. Malfertheiner,et al.  A meta‐analysis comparing eradication, healing and relapse rates in patients with Helicobacter pylori‐associated gastric or duodenal ulcer , 2001, Alimentary pharmacology & therapeutics.

[22]  M. Kasuga,et al.  CYP2C19 Genotype and Pharmacokinetics of Three Proton Pump Inhibitors in Healthy Subjects , 2001, Pharmaceutical Research.

[23]  G. Sachs,et al.  Expression of the Helicobacter pylori ureI Gene Is Required for Acidic pH Activation of Cytoplasmic Urease , 2000, Infection and Immunity.

[24]  G. Sachs,et al.  A H+-gated urea channel: the link between Helicobacter pylori urease and gastric colonization. , 2000, Science.

[25]  G. Sachs,et al.  The effect of environmental pH on the proton motive force of Helicobacter pylori. , 1996, Gastroenterology.

[26]  J. Turnidge,et al.  Is bactericidal activity of amoxicillin against Helicobacter pylori concentration dependent? , 1996, Antimicrobial agents and chemotherapy.

[27]  D. Graham,et al.  Variability with omeprazole-amoxicillin combinations for treatment of Helicobacter pylori infection. , 1995, The American journal of gastroenterology.

[28]  M. Blaser,et al.  The proton pump inhibitor omeprazole inhibits acid survival of Helicobacter pylori by a urease-independent mechanism. , 1994, Gastroenterology.

[29]  T. C. Diss,et al.  Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori , 1993, The Lancet.

[30]  H. Satoh,et al.  Potent inhibitory action of the gastric proton pump inhibitor lansoprazole against urease activity of Helicobacter pylori: unique action selective for H. pylori cells , 1993, Antimicrobial Agents and Chemotherapy.

[31]  W. Craig,et al.  Continuous infusion of beta-lactam antibiotics , 1992, Antimicrobial Agents and Chemotherapy.

[32]  H. Satoh,et al.  Lansoprazole, a novel benzimidazole proton pump inhibitor, and its related compounds have selective activity against Helicobacter pylori , 1991, Antimicrobial Agents and Chemotherapy.

[33]  G. Eliopoulos,et al.  Effect of varying pH on the susceptibility ofCampylobacter pylori to antimicrobial agents , 1989, European Journal of Clinical Microbiology and Infectious Diseases.

[34]  J. Gisbert,et al.  H. pylori eradication therapy vs. antisecretory non-eradication therapy (with or without long-term maintenance antisecretory therapy) for the prevention of recurrent bleeding from peptic ulcer. , 2003, The Cochrane database of systematic reviews.

[35]  G. Lindberg,et al.  Prolonged and profound acid inhibition is crucial in Helicobacter pylori treatment with a proton pump inhibitor combined with amoxicillin. , 1998, Scandinavian journal of gastroenterology.